Cell line · CVCL_0480
Papers348
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 348
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Long Noncoding RNA LINC00941 Links Oncogenic KRAS Signaling to Aggressiveness, DNA Repair, and Chemoresistance in Pancreatic Cancer | IUBMB Life | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacokinetic Tuning Redirects β‐Lapachone From NQO1 Bioactivation to Vimentin‐Targeted Oxidation in Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genetically engineered RNA inducers of proximity for protein regulation. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Selective AUTAC-mediated ATP7B degradation unlocks cuproptosis vulnerability in pancreatic ductal adenocarcinoma. | Clin Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cytotoxic Dihydroagarofuran Sesquiterpenoids Isolated From the Roots of Tripterygium wilfordii. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Remodeling of mitochondrial dynamics by metabolic pathways couples to oncogenic growth in GNAS (Gαs) mutant pancreas cancer. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Immunomagnetic-MXene Bifunctional Probes for Ultrasensitive and Specific Terahertz Metasensing of Tumor-Derived Exosomes. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic Efficacy and Safety of Intraperitoneally Administered 211At-Labeled Gold Nanoparticles for Peritoneally Disseminated Malignancies. | Pharmaceutics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| STING agonist profiling by nucleotide library defines structural determinants of cyclic dinucleotide recognition. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0480/papers